Publication | Closed Access

Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose

MedicinePhase IiiClinical TrialsHepatitisTherapeutic EfficacyAntiviral TherapyTreatment OptionPharmacotherapySafety ResultsAntiviral DrugPeginterferon Alfa-2aPharmacology